Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Noam PondeIan BradburyMatteo LambertiniMichael EwerChristine CampbellHelene AmeelsDimitrios ZardavasSerena Di CosimoJosé BaselgaJens HuoberMiguel IzquierdoDebora FumagalliIvana Bozovic-SpasojevicMarion MaetensNadia HarbeckLajos PusztaiMichael BerghornYoung-Hyuck ImManuel Ruiz BorregoDar-Ren ChenRichard RodehefferMartine PiccartThomas SuterEvandro de Azambuja

Published in: Breast cancer research and treatment (2017)

These results suggest that TnT and proBNP may not be useful as early predictors of cardiac toxicity in anthracycline-naïve patients receiving trastuzumab and/or lapatinib.

Keyphrases

metastatic breast cancer
early stage
epidermal growth factor receptor
left ventricular
positive breast cancer
high glucose
oxidative stress
diabetic rats
drug induced
squamous cell carcinoma
heart failure
endothelial cells
atrial fibrillation
tyrosine kinase
breast cancer risk
neoadjuvant chemotherapy